+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Life Sciences Real-World Evidence Solutions, 2025: Frost Radar™ Report

  • Report

  • May 2025
  • Region: Global
  • Frost & Sullivan
  • ID: 6098000

A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines

The evolving IT landscape has played a transformative role in the field of life sciences, enabling a reliance on real-world evidence (RWE) solutions. With growing competition and the demand for precision in decision-making, pharmaceutical companies, healthcare providers, and technology organizations have realized the need for real-world data (RWD) to boost research while optimizing clinical trials and improving patient outcomes.

The platforms and enabling technologies help pharma/biotech companies harness regulatory-grade RWE across the product lifecycle, including early-stage research, clinical development, launch planning, value-based contracting, long-term patient monitoring, and patient activation.

The life sciences RWE solutions industry is fragmented, with about 120 vendors operating in this space across areas including data aggregation, integration, interoperability, and predictive analytics to provide pharmaceutical companies with high-quality insights.

The publisher screened and analyzed more than 45 RWE solution vendors and short-listed the leading 16 companies based on a detailed analysis of their corporate growth potential and ability to drive visionary innovation in this industry. This Frost Radar™ benchmarks companies primarily in data integration, management, analytics, and insights with a strong play in the data collection segment. Solutions in other segments and enabling technologies had a positive impact on their ratings.

When benchmarking vendors, the publisher evaluated their portfolios across key criteria, such as data integration, data quality, advanced analytics, scalability, real-time access, cloud support, collaboration, regulatory expertise, patient-centric approaches, innovation, agility, and cost-effectiveness to ensure that life sciences companies partner with the best vendor for their evolving and customized needs.

The publisher analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar™. The publication presents competitive profiles of each company on the Frost Radar™ considering their strengths and the opportunities that best fit those strengths.

Table of Contents

Frost Radar™: Life Sciences Real-World Evidence Solutions, 2025Strategic Imperative and Growth EnvironmentFrost Radar™: Life Sciences Real-World Evidence Solutions
Frost Radar™: Companies to Action
  • Aetion
  • Clarify Health
  • COTA Healthcare
  • Flatiron Health
  • Inovalon
  • IQVIA
  • Komodo Health
  • Merative
  • OM1
  • Optum Life Sciences
  • Oracle Health
  • Pharmaceutical Product Development
  • Picnic Health
  • TriNetX
  • Verana Health
  • Veradigm
Best Practices & Growth Opportunities
  • Best Practices
  • Growth Opportunities
Frost Radar™ Analytics
Next Steps: Leveraging the Frost Radar™ to Empower Key Stakeholders
  • Significance of Being on the Frost Radar™
  • Frost Radar™ Empowers the CEO’s Growth Team
  • Frost Radar™ Empowers Investors
  • Frost Radar™ Empowers Customers
  • Frost Radar™ Empowers the Board of Directors
Legal Disclaimer